Saturday, August 15, 2026
Knowledge FilesExploreSearch
Via News
Facts you can rely on·101 entities·4,806 sourced facts
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)

View original at globenewswire.com
GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC) BOCA RATON, FL AND TORONTO, ONTARIO, March 16, 2026 (GLOBE NEWSWIRE) -- GNQ Insilico Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GNQ is well-positioned to capture meaningful market share

    60% confidence

  • The transaction provides resources and public market visibility to expand commercial partnerships and scale solutions to serve pharmaceutical companies, investors and healthcare providers worldwide

    60% confidence

  • GNQ's integration of Genomics, Artificial Intelligence, and Quantum Computing represents a differentiated approach to addressing significant challenges facing drug discovery and development

    60% confidence

  • GNQ's Drug Simulation Platform and Digital Twins Platform are slated for release later in 2026

    60% confidence

  • The Transaction is expected to provide approximately $15 million in proceeds to GNQ, including a PIPE of up to $10 million and cash held in IBAC trust account

    60% confidence

  • Partnering with IB Acquisition Corp. marks a pivotal moment for GNQ as we scale our three comprehensive AI-powered platforms to transform pharmaceutical R&D and healthcare delivery

    60% confidence

  • The Transaction is expected to close in the third quarter of 2026

    60% confidence

Cited in these Via News reports